« Return to News | Drug Sponsors

Evotec to close Indian chemistry operations

Monday, July 8, 2013 02:19 PM

Hamburg, Germany-based Evotec will close its chemistry operations in Thane, India. All chemistry work now will be performed at its Abingdon, U.K., facility, to address to an increasing requirement to operate closer to the principal R&D laboratories of major customers. All project work in Thane will be completed by the end of September, and Evotec (India) Private will then wind down.

As a result, the company will cut 120 people and Evotec will take a one-time impairment charge.

“Evotec was due to relocate its Indian chemistry operations in June 2014,” said Dr. Mario Polywka, COO of Evotec. “During the due diligence in finding a new facility and because of growing customer requirements for European-based activities, we came to the conclusion to exit our operations in India completely. Through this realignment we will be able to most efficiently serve our customers, utilize our U.K. chemistry resources and capabilities and also realize some cost savings. Unfortunately, the impact is that we must say goodbye to a first-class work force in Thane that has so ably supported our customers over the last four years.”

Evotec (India) Private is a 100% subsidiary of Evotec. Its offerings include custom synthesis, process research and development, scale-up and analytical services.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.